Ligand(LGND) - 2023 Q3 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From ______ to ______ . Commission File Number: 001-33093 LIGAND PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 3911 Sorrento Valley Boulevard, Suite 110 Washington, D.C. 20549 _____________________________________________________________________ ...